Neil K. Warma, President & CEO, Opexa Therapeutics, explains Opexa’s goal to create the first personalized therapy for patients with multiple sclerosis. He discusses the ABILI-T Phase 2 Clinical Trial that aims to treat patients with secondary progressive multiple sclerosis using precision T-cell immunotherapy.

Resources & References:

http://www.clinicaltrials.gov/ct2/show/NCT01684761?term=opexa&rank=3

http://www.opexatherapeutics.com/

http://www.nationalmssociety.org/What-is-MS